Document is current

Any future updates will be listed below

Prospective phase II trial of first-line rituximab, methotrexate, and orelabrutinib (R-MO) in primary central nervous system lymphoma

Crossref DOI link: https://doi.org/10.1038/s41408-025-01278-w

Published Online: 2025-04-29

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark